Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
Biogen Inc.’s Head of Development, Priya Singhal, reported equity transactions involving company stock. On January 30, 2026, 1,829 shares of common stock were acquired at $0 following the vesting and exercise of a restricted stock unit award granted on February 1, 2023 that vests in three equal annual installments.
Also on January 30, 2026, 582 shares were surrendered at $179.89, and on February 2, 2026, 748 shares were sold at $179.3. After these transactions, Singhal directly held 6,271.1428 shares of Biogen common stock.
A holder of 748 shares of common stock of a NASDAQ-listed company has filed a notice of proposed sale under Rule 144. The shares have an aggregate market value of 134116.40 and are planned to be sold on 02/02/2026 through Fidelity Brokerage Services LLC on NASDAQ.
The securities were recently acquired on 02/01/2026 via restricted stock vesting from the issuer as compensation. The filer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Biogen Inc. is signaling a sizeable one-time expense in its upcoming fourth-quarter 2025 results. The company expects to record approximately $222 million of acquired in-process research and development, upfront and milestone expense on a pre-tax basis, which it estimates will reduce GAAP and non-GAAP net income per diluted share for the quarter by about $1.26.
This line item reflects costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions. Biogen began presenting this expense as a separate line item in its income statement in the first quarter of 2025 and notes that it does not forecast such costs because their timing and size are inherently uncertain. The company also emphasizes that its results for the quarter ended December 31, 2025 are preliminary and may change as normal closing procedures are completed.
Biogen Inc. President and CEO Christopher A. Viehbacher reported equity transactions in the company’s common stock. On December 1, 2025, 7,040 shares of common stock were acquired at a price of $0 per share through the exercise of previously granted restricted stock units, coded as transaction type M. On the same date, 3,404 shares of common stock were disposed of in a transaction coded F at a price of $177.78 per share. After these transactions, Viehbacher beneficially owned 16,443 shares of Biogen common stock directly. The underlying restricted stock unit award, originally granted on December 1, 2022, vested on its third anniversary and represented one share of common stock for each unit.
Biogen Inc. (BIIB) reported insider equity activity by its Head of Research. On 10/31/2025, 695 shares of common stock were acquired at $0 under a transaction coded M, reflecting settlement of previously granted RSUs. A separate transaction coded F covered 337 shares at $154.27. Following these transactions, the officer directly owned 1,791 shares of common stock.
The derivative table shows 695 restricted stock units outstanding after the activity, tied to an award granted on 11/01/2023 that vests in three equal annual installments beginning on 11/01/2024, with an expiration date of 11/01/2026.
Biogen Inc. reported Q3 2025 results in its 10-Q. Total revenue was $2,534.7 million, led by product revenue of $1,846.9 million, anti‑CD20 therapeutic programs of $493.9 million, Alzheimer’s collaboration revenue of $42.7 million, and contract manufacturing, royalty and other revenue of $151.2 million.
Operating lines showed cost of sales of $674.4 million, R&D of $436.1 million, and SG&A of $594.8 million. Net income was $466.5 million, with diluted EPS of $3.17. Comprehensive income reached $489.8 million.
On the balance sheet, cash and cash equivalents were $3,862.8 million, total assets $29,207.5 million, and notes payable $6,285.1 million. Year‑to‑date, operating cash flow was $1,692.7 million, investing cash flow $(139.4) million, and financing cash flow $(164.9) million. Shares outstanding were 146,702,272 as of October 28, 2025.
Biogen Inc. (BIIB) furnished third-quarter results. The company submitted a press release announcing results of operations and financial condition for the quarter ended September 30, 2025, furnished as Exhibit 99.1.
The press release was provided under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. Biogen’s common stock trades on the Nasdaq Global Select Market under the symbol BIIB.
Biogen Inc. announced a preliminary estimate for the quarter ended September 30, 2025: it expects approximately $2 million of acquired in‑process research and development, upfront and milestone expense. The company estimates this will reduce GAAP and non‑GAAP net income per diluted share for Q3 2025 by about ($0.01) per share.
Biogen began presenting this expense as a separate line item starting in the first quarter of 2025 to reflect costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in‑process R&D. Results for the quarter have not been finalized and remain subject to financial statement closing procedures.
Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on
Priya Singhal, Head of Development at Biogen Inc. (BIIB), reported a series of equity transactions dated 08/29/2025 and 09/02/2025. A grant of 1,669 restricted stock units (RSUs) vested (recorded as an acquisition at $0) increasing her beneficial ownership before sales to 7,096.1428 shares. On 08/29/2025 she sold 807 shares at $132.22 and on 09/02/2025 she sold 517 shares at $133.55, leaving her with 5,772.1428 shares following the reported transactions. The filing notes the RSU award was granted on September 1, 2022 and vests in three equal annual installments.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
